The patients in the nivolumab-plus-ipilimumab group received the combination of nivolumab at a dose of 240 mg and ipilimumab at a dose of 1 mg per kilogram of body weight, administered ...

The FDA received a biologics license application for accelerated approval of RP1 plus nivolumab for advanced, pretreated ...

The FDA has received a biologics license application submission for RP1 plus nivolumab in patients with PD-1 ...